- NeutroSpec Receives FDA Approval
- Palatin Technologies, Inc. has
received full approval from the FDA to market NeutroSpec™, indicated
for the diagnosis of appendicitis in patients with equivocal signs.
NeutroSpec will be marketed and distributed Mallinckrodt Imaging.
Click here to review the package
- Stark II Still Allows for
In-Office Radiology Services
- In late March, the Centers for
Medicare and Medicaid Services published Phase II of the Stark II
rules, a new set of physician self-referral restrictions that take
effect July 26. The fundamental premise of Stark is this: If a
physician or a member of a physician's immediate family has a
financial relationship with a healthcare facility, the physician may
not refer Medicare or Medicaid patients to that facility for
designated health services such as radiology unless an exception
applies. Nuclear medicine is excluded from the Stark
For more information...
- Holmium-166 DOTMP
- NeoRx has filed an investigational
new drug (IND) application with the FDA for a phase II clinical
study of its Skeletal Targeted Radiotherapy (STR) Ho-166 DOTMP in
patients with breast cancer that has metastasized to the bone. After
injection Ho-166 DOTMP rapidly binds to bone mineral, delivering a
brief, intense dose of radiation to destroy cancer cells in the bone
For more information....
Comments or Suggestions?
Let us know your thoughts about the newsletter.
email does not view graphics properly go to
Brought to you by
- © 2004 Nuclear Education Online
- 4301 W. Markham #522
- Little Rock, AR 72205
- For more information, contact
radiation warning symbol, as we currently know it,
was "doodled" out at the University of California
Radiation Laboratory in Berkeley sometime in 1946
by a small group of people. "A number of people in
the group took an interest in suggesting different
motifs, and the one arousing the most interest was
a design which was supposed to represent activity
radiating from an atom."
The first signs printed at Berkeley had a magenta
symbol on a blue background. The magenta was
selected because "it was distinctive and did not
conflict with any color code that we were familiar
with. Another factor in its favor was its cost. . .
The high cost will deter others from using this
color promiscuously." The original blue background
was later changed to yellow for visibility. For
more information about the history of the radiation
The patient is a 31 year old white
female who presented with right upper quadrant and epigastric pain.
She had several days of persistent pain from right breast to her
- To subscribe to this mailing list